Abstract
Chronic hepatitis C (CHC) constitutes a major health concern. Hepatitis C virus eradication by antiviral treatment can markedly reduce the risk of developing cirrhosis, hepatocellular carcinoma and liver-related death. A plethora of new direct antiviral agents have been developed and are being explored in clinical trials. One of the newest members of this family is the NS3/4A protease inhibitor ABT-450. The multi-targeted approach combining ritonavir-enhanced ABT-450 with ombitasvir and dasabuvir has been evaluated for the treatment of CHC Gt1 in treatment-naïve and treatment-experienced adults. In this article, we sought to discuss the current knowledge on ABT-450-containing regimens, with special emphasis on treatment-experienced CHC Gt1 patients. This new combination was found to be potent, safe and well tolerated. Future Phase III trials with larger sample size in patients with decompensated cirrhosis, non-Gt1, end-stage renal disease and liver transplant recipients are eagerly awaited.
Keywords:
ABT-450; HCV; NS3/4A; antiviral treatment; dasabuvir; interferon-free; ombitasvir.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
2-Naphthylamine
-
Anilides / therapeutic use
-
Antiviral Agents / therapeutic use*
-
Carbamates / therapeutic use
-
Carcinoma, Hepatocellular / virology
-
Clinical Trials, Phase II as Topic
-
Clinical Trials, Phase III as Topic
-
Cyclopropanes
-
Drug Interactions
-
Drug Resistance, Viral
-
Drug Therapy, Combination
-
Genotype
-
Hepacivirus / genetics*
-
Hepatitis C, Chronic / complications*
-
Hepatitis C, Chronic / drug therapy*
-
Humans
-
Lactams, Macrocyclic
-
Liver Cirrhosis / virology
-
Liver Neoplasms / virology
-
Macrocyclic Compounds / therapeutic use*
-
Proline / analogs & derivatives
-
Protease Inhibitors / therapeutic use*
-
RNA, Viral
-
Randomized Controlled Trials as Topic
-
Ribavirin / therapeutic use*
-
Ritonavir / therapeutic use
-
Sulfonamides / therapeutic use
-
Uracil / analogs & derivatives
-
Uracil / therapeutic use
-
Valine
Substances
-
Anilides
-
Antiviral Agents
-
Carbamates
-
Cyclopropanes
-
Lactams, Macrocyclic
-
Macrocyclic Compounds
-
Protease Inhibitors
-
RNA, Viral
-
Sulfonamides
-
ombitasvir
-
Ribavirin
-
Uracil
-
Proline
-
2-Naphthylamine
-
dasabuvir
-
Valine
-
Ritonavir
-
paritaprevir